ACM Q2-19
Comment
2024-12-20
Comment on STENOCARE’s Announcement of a Conditional Rights Issue of up to DKK 20.2m
2024-12-17
Comment on STENOCARE’s Approval for a new Medical Cannabis CBD100 oil
2024-12-13
Comment on Pharma Equity Group’s New Execution Strategy
2024-12-02
Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway
2024-11-27
Comment on STENOCARE Shifting Strategy to Focus on Trading and Exit from Production
